{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:26:52Z","timestamp":1794540412921,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41591-025-03763-y","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:02:49Z","timestamp":1751000569000},"page":"3074-3080","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8840-7934","authenticated-orcid":false,"given":"Susana","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-0387","authenticated-orcid":false,"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-4237","authenticated-orcid":false,"given":"Alvaro Ingles","family":"Garces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky Sanchez","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2918-1370","authenticated-orcid":false,"given":"Angelika","family":"Terbuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reece","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Grochot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6118-1097","authenticated-orcid":false,"given":"Mahtab","family":"Rouhifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-8872","authenticated-orcid":false,"given":"Ruth","family":"Ruddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-8078","authenticated-orcid":false,"given":"Bora","family":"Gurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6572-1293","authenticated-orcid":false,"given":"Karen","family":"Swales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Prout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-4100","authenticated-orcid":false,"given":"Mona","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9314","authenticated-orcid":false,"given":"Stefan","family":"Symeonides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5207-3864","authenticated-orcid":false,"given":"Jan","family":"Rekowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-2514","authenticated-orcid":false,"given":"Christina","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Paschalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8321-4212","authenticated-orcid":false,"given":"Juanita","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-7101","authenticated-orcid":false,"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann Sebastian","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-3123","authenticated-orcid":false,"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"3763_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30\u201339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3763_CR2","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867\u20131876 (2014).","journal-title":"N. Engl. J. Med."},{"key":"3763_CR3","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632\u20131643 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3763_CR4","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1200\/JCO.21.00714","volume":"40","author":"AL Ho","year":"2022","unstructured":"Ho, A. L. et al. Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase III, randomized, placebo-controlled trial (ASTRA). J. Clin. Oncol. 40, 1870\u20131878 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3763_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss, B. D. et al. NF106: a Neurofibromatosis Clinical Trials Consortium phase II Trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J. Clin. Oncol. 39, 797\u2013806 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3763_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","volume":"21","author":"JC Dawson","year":"2021","unstructured":"Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D. & Frame, M. C. Targeting FAK in anticancer combination therapies. Nat. Rev. Cancer 21, 313\u2013324 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"3763_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41418-018-0210-8","volume":"26","author":"J Rozanc","year":"2019","unstructured":"Rozanc, J. et al. Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma. Cell Death Differ. 26, 1365\u20131378 (2019).","journal-title":"Cell Death Differ."},{"key":"3763_CR8","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1158\/1078-0432.CCR-20-3363","volume":"27","author":"JS Paradis","year":"2021","unstructured":"Paradis, J. S. et al. Synthetic lethal screens reveal cotargeting FAK and MEK as a multimodal precision therapy for GNAQ-driven uveal melanoma. Clin. Cancer Res. 27, 3190\u20133200 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3763_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","volume":"183","author":"B McNamara","year":"2024","unstructured":"McNamara, B. et al. Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecol. Oncol. 183, 133\u2013140 (2024).","journal-title":"Gynecol. Oncol."},{"key":"3763_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","volume":"120","author":"G Mak","year":"2019","unstructured":"Mak, G. et al. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. Br. J. Cancer 120, 975\u2013981 (2019).","journal-title":"Br. J. Cancer"},{"key":"3763_CR11","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1158\/0008-5472.CAN-12-3937","volume":"73","author":"N Ishii","year":"2013","unstructured":"Ishii, N. et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 73, 4050\u20134060 (2013).","journal-title":"Cancer Res."},{"key":"3763_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito, P. et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697\u2013710 (2014).","journal-title":"Cancer Cell"},{"key":"3763_CR13","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/S1470-2045(20)30464-2","volume":"21","author":"C Guo","year":"2020","unstructured":"Guo, C. et al. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766\/VS-6766 in patients with RAS\/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol. 21, 1478\u20131488 (2020).","journal-title":"Lancet Oncol."},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones, S. F. et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest. New Drugs 33, 1100\u20131107 (2015).","journal-title":"Invest. New Drugs"},{"key":"3763_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","volume":"139","author":"DE Gerber","year":"2020","unstructured":"Gerber, D. E. et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer 139, 60\u201367 (2020).","journal-title":"Lung Cancer"},{"key":"3763_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell, D. A. et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-a double-blind, randomized, phase II study. J. Clin. Oncol. 37, 790\u2013798 (2019).","journal-title":"J. Clin. Oncol."},{"key":"3763_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cct.2004.12.007","volume":"26","author":"M Gonen","year":"2005","unstructured":"Gonen, M. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. Contemp. Clin. Trials 26, 131\u2013140 (2005).","journal-title":"Contemp. Clin. Trials"},{"key":"3763_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1200\/JCO.21.02371","volume":"41","author":"PK Brastianos","year":"2023","unstructured":"Brastianos, P. K. et al. Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations. J. Clin. Oncol. 41, 618\u2013628 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3763_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1053\/j.seminoncol.2016.06.001","volume":"43","author":"U Banerji","year":"2016","unstructured":"Banerji, U. & Workman, P. Critical parameters in targeted drug development: the pharmacological audit trail. Semin. Oncol. 43, 436\u2013445 (2016).","journal-title":"Semin. Oncol."},{"key":"3763_CR20","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-12-0742","volume":"18","author":"M Martinez-Garcia","year":"2012","unstructured":"Martinez-Garcia, M. et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK\/RAF inhibitor in patients with solid tumors. Clin. Cancer Res. 18, 4806\u20134819 (2012).","journal-title":"Clin. Cancer Res."},{"key":"3763_CR21","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","volume":"77","author":"T Shimizu","year":"2016","unstructured":"Shimizu, T. et al. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 77, 997\u20131003 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"3763_CR22","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","volume":"28","author":"B Manning-Geist","year":"2022","unstructured":"Manning-Geist, B. et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin. Cancer Res. 28, 4456\u20134465 (2022).","journal-title":"Clin. Cancer Res."},{"key":"3763_CR23","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.20.01164","volume":"38","author":"BJ Monk","year":"2020","unstructured":"Monk, B. J. et al. MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J. Clin. Oncol. 38, 3753\u20133762 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3763_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","volume":"14","author":"J Farley","year":"2013","unstructured":"Farley, J. et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 14, 134\u2013140 (2013).","journal-title":"Lancet Oncol."},{"key":"3763_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","volume":"399","author":"DM Gershenson","year":"2022","unstructured":"Gershenson, D. M. et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial. Lancet 399, 541\u2013553 (2022).","journal-title":"Lancet"},{"key":"3763_CR26","doi-asserted-by":"publisher","first-page":"e076387","DOI":"10.1136\/bmj-2023-076387","volume":"383","author":"C Yap","year":"2023","unstructured":"Yap, C. et al. Enhancing reporting quality and impact of early phase dose-defining clinical trial: CONSORT dose-finding extension (CONSORT-DEFINE) guidance. Br. Med. J. 383, e076387 (2023).","journal-title":"Br. Med. J."},{"key":"3763_CR27","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1158\/1535-7163.MCT-18-0727","volume":"18","author":"A Stewart","year":"2019","unstructured":"Stewart, A. et al. Differences in signaling patterns on PI3K inhibition reveal context specificity in KRAS-mutant cancers. Mol. Cancer Ther. 18, 1396\u20131404 (2019).","journal-title":"Mol. Cancer Ther."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03763-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:09:50Z","timestamp":1788516590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03763-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03763-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5632942\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. has received honoraria for consulting and\/or advisory board work from AbbVie, AstraZeneca, BioNTech, Eisai, Gilead, GlaxoSmithKline, Grey Wolf Therapeutics, Immunogen, Incyte, ITM Oncologics, Lilly, Merck Sharpe Dohme, Mersana, Myriad, Oncxerna, Pharmaand, Seagen, TORL BioTherapeutics, Verastem, Zymeworks; honoraria and\/or expenses from AbbVie, AstraZeneca, GlaxoSmithKline, Immunogen, Merck Sharpe Dohme, Mersana, Takeda, Verastem and Zymeworks; research funding from AstraZeneca, GlaxoSmithKline; and PI for Global\/ENGOT lead RAMP201 and ENGOT lead RAMP301 (Verastem-sponsored). M.G.K. has a consulting or advisory role with Bayer, Guardant Health, Janssen, Roche, Seattle Genetics and Zai Lab; has received speaker fees from BMS, Eisai, Janssen, Roche and Servier; travel, accommodation or expenses from BerGenBio, BMS, Janssen, Roche, Servier and Zai Lab; and research grants from Novartis and Roche. A.G. declares no competing interests. A.I.G. declares no competing interests. V.S.P. declares no competing interests. A.T. declares no competing interests. R.S. has received travel expenses from Bayer and for educational symposia from AstraZeneca. R.C. declares no competing interests. R.G. declares no competing interests. M.R. is an Institute for Cancer Research (ICR) employee. R.R. is an ICR employee. R.G. is an ICR employee. K.S. is an ICR employee. N.T. declares no competing interests. T.P. is an ICR employee. M.P. is an ICR employee. S.S. has received research grants from Verastem Oncology, Merck Sharpe Dohme; advisory board honoraria from Ellipses Pharma and Exscientia\/Recursion; and is on the nonremunerated advisory board of Duke Street Bio, Ellipsis, Grey Wolf Therapeutics, Merck Sharp and Dohme and Roche. J.R. has received an advisory board honorarium from Novartis and is an ICR employee. C.Y. is an ICR employee and has received honoraria Faron Pharon Pharmaceuticals, Bayer, Trogenix and Merck. A.S. is an ICR employee; has received travel support from Sanofi, Roche-Genentech and Nurix; honoraria as a speaker from Astellas Pharma and Merck Sharp Dohme; and is on the advisory board of DE Shaw Research, CHARM therapeutics, Ellipses Pharma and Droia Ventures. A.P. declares no competing interests. J.L. has received research grants from Roche-Genentech, Astex, Merck Sharp Dohme, Janssen and Verastem Oncology; and is on the advisory boards of Basilia, Roche, GlaxoSmithKline and Servier. A.M. has received research grants Astex, Merck and Merck Sharp Dohme; honoraria from Chugai, Faron, Merck, GlaxoSmithKline, Seagen, Takeda and Janssen; travel support from Amgen and Janssen; and is on the advisory boards of Imugene, Jansson, Merck, Takeda, Merck Sharp Dohme, Genmab, Pfizer, AstraZeneca and Immutep. J.S.d.B. is an ICR employee, named as an inventor, with no financial interest for patent 8,822,438, submitted by Janssen that covers the use of abiraterone acetate with corticosteroids; has received research support from AstraZeneca, Cellcentric, Crescendo, Daiichi, Immunic Therapeutics, MetaCurUm, Myricx, Nurix, Oncternal, Orion and Sanofi Aventis; honoraria from advisory boards of AbbVie, Acai Therapeutics, Amgen, Amunix, Astellas, Bayer, Bioxcel Therapeutics, Celcuity, Crescendo, Daiichi, Dark Blue Therapeutics, Duke Street Bio, Dunad Therapeutics, Endeavor Biomedicines INC, Genentech-Roche, GSK, Macrogenics, Merck Serono, MetaCurUm, Moma Therapeutics, Myricx, Novartis, Nurix, Nuvation Bio, One-Carbon Therapeutics, Oncternal, Orion, Page Therapeutics, Peptone, Pfizer, Takeda, Tango Therapeutics, Tubulis, GmbH and VIR Biotechnology. U.B. is an ICR employee, named as an inventor on patents arising from this trial, ICR has has entered into a license agreement with Verastem Oncology and UB is due to receive a proportion of income arising from this license in accordance with the institute's rewards to discoverers policy; has received research grants from Verastem Oncology, Chugai and Avacta; and honoraria for advisory board work from Carrick Therapeutics, Pharmenable, Ellipses, Amalus Therapeutics, Dania Therapeutics and Pegascy. The Institute of Cancer Research has commercial interests in CYP17, AKT, CHK1, RAF, MPS1, FLT3\/Aurora Kinase inhibitors, GCN2 activators, molecular glues and folate targeted thymidylate synthetase inhibitors.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}